by The global Lupus Therapeutic Market is estimated to be valued at US$ 3035.59 Mn in 2023 and is expected to exhibit a CAGR of 8.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
The lupus therapeutic market consists of drugs being used to treat systemic lupus erythematosus (SLE), which is an autoimmune disease where the immune system of the body mistakenly attacks healthy cells and tissues. SLE can affect various parts of the body including joints, skin, kidneys, blood cells, brain, heart and lungs. Currently available lupus therapeutics include corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), antimalarial drugs, immunosuppressive drugs and biologics. Corticosteroids help reduce inflammation and pain associated with lupus. NSAIDs are primarily used to relieve joint pain and swelling. Antimalarial drugs such as hydroxychloroquine are the first line of treatment and help reduce disease activity and flares. Immunosuppressive drugs like azathioprine help prevent organ damage by suppressing the immune system. Biologics target specific molecules involved in the immune response and show promise in managing lupus.
Market key trends:
One of the major trends in the lupus therapeutic market is the rising pipeline of drugs in clinical trials. Several biologics targeting molecules like B-lymphocyte stimulator (BLyS), interleukin 6 (IL-6), cytokine and complement pathways are under evaluation for efficacy and safety in treating lupus. For instance, Belimumab was the first biological therapy approved by FDA in 2011 for treatment of SLE. Another key trend is the increasing focus on developing combination therapies to achieve remission and reduce disease relapse in SLE patients. Combining drugs that suppress immune system with biologics help manage both inflammation and specific pathways simultaneously. Also, many companies are exploring novel drug delivery systems like nanocarriers to enhance bioavailability and efficacy of existing drugs.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is moderate as the lupus therapeutics market requires extensive R&D and high capital investments for drug development.
Bargaining power of buyers: The bargaining power of buyers is moderate as the demand for lupus therapeutics is inelastic in nature given its life-saving applications.
Bargaining power of suppliers: The bargaining power of suppliers is low due to the presence of a large number of medium and small suppliers in the market.
Threat of new substitutes: The threat of new substitutes is low as lupus has limited treatment options currently.
Competitive rivalry: High due to presence of many global and local players competing on basis of pricing and product innovation.
Key Takeaways
The Global Lupus Therapeutics Market Size is expected to witness high growth, exhibiting CAGR of 8.6% over the forecast period, due to increasing prevalence of lupus globally. The market size for 2023 is estimated to be US$ 3035.59 Mn.
Regional analysis: North America is expected to dominate the global lupus therapeutics market during the forecast period owing to increasing awareness about lupus, presence of advanced healthcare facilities and higher healthcare spending. Asia Pacific is anticipated to exhibit the fastest growth rate over the forecast period due to improving healthcare infrastructure and growing medical tourism in the region.
Key players operating in the lupus therapeutics market are Hikma Pharmaceuticals PLC, Lupus Therapeutics, Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline plc, Amgen Inc., Novartis AG, Sanofi, UCB S.A., ImmuPharma PLC, Bayer AG, Merck & Co., Inc., Aurinia Pharmaceuticals Inc., Pfizer Inc., ADMA Biologics, Inc., AstraZeneca, F.Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Boehringer Ingelheim International Gmbh.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
